LGVN News and Press, Longeveron Inc. From 12/03/21

3 Top Health Care Stocks To Watch In December 2021 As the broader stock market looks to end this rollercoaster ride of a week in the green, one fact remains. Namely, the Omicron Covid variant is the latest hurdle in the fight against the pandemic and health care stocks are o...

Friday's midday trading saw Zillow (NASDAQ:Z)(NASDAQ:ZG) recover a portion of the losses it suffered after its sudden decision recently to close down its home-flipping business. The stock gained after the company revealed progress in winding down the inventory of homes it stockpiled during th...

Gainers: Celyad (NASDAQ:CYAD) +35%. Longeveron (NASDAQ:LGVN) +29%. Marvell Technology (NASDAQ:MRVL) +18%. Petros Pharmaceuticals (NASDAQ:PTPI) +17%. CTI BioPharma (NASDAQ:CTIC) +16%. Tilly's (NYSE:TLYS) +14%. Krispy Kreme (NASDAQ:DNUT) +10%. PetIQ (NASDAQ:PETQ) +9%. Vicinity (NASDAQ:VEV) +9%....

Shares of Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company headquartered in Miami, are soaring in response to good news from the U.S. Food and Drug Administration (FDA). Investors excited about an orphan drug designation for the company's stem cell treatment pushed...

Gainers: Celyad Oncology CYAD +41%, Longeveron LGVN +28%, Petros Pharmaceuticals (NASDAQ:PTPI) +26%, AirSculpt Technologies AIRS +12%, Werewolf Therapeutics (NASDAQ:HOWL) +12%. Losers: Esperion Therapeutics ESPR -40%, Biofrontera (NASDAQ:...

Celyad Oncology (NASDAQ:CYAD) +31% raises $32.5M in private placement with Fortress Investment Group. Longeveron (NASDAQ:LGVN) +26% on FDA orphan designation to Lomecel-B Marvell Technology (NASDAQ:MRVL) +22% after third-quarter earnings beat Code Chain New Continent ...

Longeveron (NASDAQ:LGVN) soars 29.1% premarket after FDA granted orphan designation to Lomecel-B, its allogeneic bone marrow-derived mesenchymal stromal cells, or MSCs, as a treatment of Hypoplastic Left Heart Syndrome. Among the benefits of Orphan Drug status in the U.S. is a seven...

Gainers: Arbutus Biopharma (NASDAQ:ABUS) +87%. MDJM (NASDAQ:MDJH) +41%. Context Therapeutics (NASDAQ:CNTX) +35%. Build-A-Bear Workshop (NYSE:BBW) +33%. Ardelyx (NASDAQ:ARDX) +28%. Ambarella (NASDAQ:AMBA) +25%. Roivant Sciences (NASDAQ:ROIV) +22%. Stran & Company (NASDAQ:STRN) +20%. Marpai...

MIAMI, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that it entered into a securities purchase agr...

After two consecutive sessions of double-digit losses, Longeveron (LGVN +9.1%) turned positive after announcing an agreement with two Japanese institutions to conduct a Phase 2 trial for Lomecel-B for older, frail subjects in the country. Per the sponsored clinical research agreement sig...